{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:30:49Z","timestamp":1792794649283,"version":"4.5.0"},"reference-count":79,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2018,6,9]],"date-time":"2018-06-09T00:00:00Z","timestamp":1528502400000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Genentech\/Roche"},{"DOI":"10.13039\/100004339","name":"Sanofi-Aventis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Roche-Genentech"},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Inventiva","id":[{"id":"https:\/\/ror.org\/03bf4tw22","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Genentech-Roche"},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>SSc is a rare CTD that affects multiple organ systems, resulting in substantial morbidity and mortality. Evidence of interstitial lung disease (ILD) is seen in \u223c80% of patients with SSc. Currently there is no approved disease-modifying treatment for ILD and few effective treatment options are available. CYC is included in treatment guidelines, but it has limited efficacy and is associated with toxicity. MMF is becoming the most commonly used medication in clinical practice in North America and the UK, but its use is not universal. Newer agents targeting the pathogenic mechanisms underlying SSc-ILD, including fibrotic and inflammatory pathways, lymphocytes, cell\u2013cell and cell\u2013extracellular membrane interactions, hold promise for better treatment outcomes, including improved lung function, patient-related outcomes and quality of life. Here we review ongoing trials of established and novel agents that are currently recruiting patients with SSc-ILD.<\/jats:p>","DOI":"10.1093\/rheumatology\/key151","type":"journal-article","created":{"date-parts":[[2018,5,17]],"date-time":"2018-05-17T07:09:55Z","timestamp":1526540995000},"page":"567-579","source":"Crossref","is-referenced-by-count":55,"title":["Ongoing clinical trials and treatment options for patients with systemic sclerosis\u2013associated interstitial lung disease"],"prefix":"10.1093","volume":"58","author":[{"given":"Dinesh","family":"Khanna","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, University of Michigan, Ann Arbor, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald P","family":"Tashkin","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P","family":"Denton","sequence":"additional","affiliation":[{"name":"Centre for Rheumatology, Division of Medicine, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin W","family":"Lubell","sequence":"additional","affiliation":[{"name":"Global Clinical Development, EMD Serono Inc., Billerica, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Vazquez-Mateo","sequence":"additional","affiliation":[{"name":"Global Clinical Development, EMD Serono Inc., Billerica, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Wax","sequence":"additional","affiliation":[{"name":"Global Clinical Development, EMD Serono Inc., Billerica, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,6,8]]},"reference":[{"key":"2019081609500511600_key151-B1","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"2019081609500511600_key151-B2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2147\/ITT.S82037","article-title":"Current perspectives on the immunopathogenesis of systemic sclerosis","volume":"5","author":"Fuschiotti","year":"2016","journal-title":"Immunotargets Ther"},{"key":"2019081609500511600_key151-B3","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative","volume":"65","author":"van den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2019081609500511600_key151-B4","first-page":"961","article-title":"Systemic sclerosis\/scleroderma: a treatable multisystem disease","volume":"78","author":"Hinchcliff","year":"2008","journal-title":"Am Fam Physician"},{"key":"2019081609500511600_key151-B5","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1136\/ard.2009.114264","article-title":"Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database","volume":"69","author":"Tyndall","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2019081609500511600_key151-B6","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/qjmed\/hcp174","article-title":"Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: a retrospective cohort study","volume":"103","author":"Nihtyanova","year":"2010","journal-title":"QJM"},{"key":"2019081609500511600_key151-B7","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.semarthrit.2008.06.002","article-title":"Determinants of morbidity and mortality of systemic sclerosis in Canada","volume":"39","author":"Al-Dhaher","year":"2010","journal-title":"Semin Arthritis Rheum"},{"key":"2019081609500511600_key151-B8","doi-asserted-by":"crossref","first-page":"247","DOI":"10.5301\/jsrd.5000214","article-title":"Gastrointestinal manifestations of systemic sclerosis","volume":"1","author":"Shreiner","year":"2016","journal-title":"J Scleroderma Relat Disord"},{"key":"2019081609500511600_key151-B9","first-page":"iii40","article-title":"Pulmonary complications: one of the most challenging complications of systemic sclerosis","volume":"48(Suppl 3)","author":"Wells","year":"2009","journal-title":"Rheumatology"},{"key":"2019081609500511600_key151-B10","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1183\/09059180.00005512","article-title":"Scleroderma lung disease","volume":"22","author":"Solomon","year":"2013","journal-title":"Eur Respir Rev"},{"key":"2019081609500511600_key151-B11","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.rdc.2015.04.006","article-title":"Management of systemic-sclerosis-associated interstitial lung disease","volume":"41","author":"Silver","year":"2015","journal-title":"Rheum Dis Clin North Am"},{"key":"2019081609500511600_key151-B12","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1183\/16000617.00002915","article-title":"Interstitial lung disease in systemic sclerosis: where do we stand?","volume":"24","author":"Cappelli","year":"2015","journal-title":"Eur Respir Rev"},{"key":"2019081609500511600_key151-B13","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1378\/chest.07-2324","article-title":"Exercise-induced pulmonary arterial hypertension in patients with systemic sclerosis","volume":"134","author":"Steen","year":"2008","journal-title":"Chest"},{"key":"2019081609500511600_key151-B14","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.3899\/jrheum.141182","article-title":"Connective tissue disease-associated interstitial lung diseases (CTD-ILD)\u2014report from OMERACT CTD-ILD Working Group","volume":"42","author":"Khanna","year":"2015","journal-title":"J Rheumatol"},{"key":"2019081609500511600_key151-B15","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1002\/art.40130","article-title":"Short-term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis","volume":"69","author":"Goh","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2019081609500511600_key151-B16","first-page":"97","article-title":"Recent treatments of interstitial lung disease with systemic sclerosis","volume":"9(Suppl 1)","author":"Yasuoka","year":"2015","journal-title":"Clin Med Insights Circ Respir Pulm Med"},{"key":"2019081609500511600_key151-B17","year":"2013"},{"key":"2019081609500511600_key151-B18","doi-asserted-by":"crossref","first-page":"e0124205","DOI":"10.1371\/journal.pone.0124205","article-title":"Safety and effectiveness of mycophenolate in systemic sclerosis. A systematic review","volume":"10","author":"Omair","year":"2015","journal-title":"PLoS One"},{"key":"2019081609500511600_key151-B19","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/acr.23282","article-title":"Efficacy of mycophenolate mofetil and oral cyclophosphamide on skin thickness: post-hoc analyses from the Scleroderma Lung Study I and II","volume":"70","author":"Namas","year":"2018","journal-title":"Arthritis Care Res"},{"key":"2019081609500511600_key151-B20","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2217\/ijr.10.112","article-title":"Cyclophosphamide as disease-modifying therapy for scleroderma: pros and cons","volume":"6","author":"Chighizola","year":"2011","journal-title":"Int J Clin Rheumatol"},{"key":"2019081609500511600_key151-B21","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s11926-009-0016-2","article-title":"Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials","volume":"11","author":"Au","year":"2009","journal-title":"Curr Rheumatol Rep"},{"key":"2019081609500511600_key151-B22","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5301\/jsrd.5000237","article-title":"Managing systemic sclerosis-related interstitial lung disease in the modern treatment era","volume":"2","author":"Volkmann","year":"2017","journal-title":"J Scleroderma Relat Disord"},{"key":"2019081609500511600_key151-B23","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N Engl J Med"},{"key":"2019081609500511600_key151-B24","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1164\/rccm.200702-326OC","article-title":"Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease","volume":"176","author":"Tashkin","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"2019081609500511600_key151-B25","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1002\/art.22204","article-title":"A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma","volume":"54","author":"Hoyles","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2019081609500511600_key151-B26","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Kowal-Bielecka","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2019081609500511600_key151-B27","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2019081609500511600_key151-B28","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.2165\/0003495-200868170-00007","article-title":"Enteric-coated mycophenolate sodium: a review of its use in the prevention of renal transplant rejection","volume":"68","author":"Sanford","year":"2008","journal-title":"Drugs"},{"key":"2019081609500511600_key151-B29","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1172\/JCI200318384","article-title":"Azathioprine: old drug, new actions","volume":"111","author":"Maltzman","year":"2003","journal-title":"J Clin Invest"},{"key":"2019081609500511600_key151-B30","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10067-005-1157-y","article-title":"A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis","volume":"25","author":"Nadashkevich","year":"2006","journal-title":"Clin Rheumatol"},{"key":"2019081609500511600_key151-B31","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/anr.1780320911","article-title":"Normotensive renal failure in systemic sclerosis","volume":"32","author":"Helfrich","year":"1989","journal-title":"Arthritis Rheum"},{"key":"2019081609500511600_key151-B32","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1002\/art.10589","article-title":"Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial","volume":"46","author":"DeMarco","year":"2002","journal-title":"Arthritis Rheum"},{"key":"2019081609500511600_key151-B33","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s004080000058","article-title":"Different expression of endothelin in the bronchoalveolar lavage in patients with pulmonary diseases","volume":"179","author":"Reichenberger","year":"2001","journal-title":"Lung"},{"key":"2019081609500511600_key151-B34","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1002\/art.27466","article-title":"Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis","volume":"62","author":"Seibold","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2019081609500511600_key151-B35","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s10875-007-9070-6","article-title":"Immunomodulatory drug CC-4047 is a cell-type and stimulus-selective transcriptional inhibitor of cyclooxygenase 2","volume":"27","author":"Ferguson","year":"2007","journal-title":"J Clin Immunol"},{"key":"2019081609500511600_key151-B36","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1182\/blood-2013-05-484782","article-title":"Pomalidomide","volume":"122","author":"Lacy","year":"2013","journal-title":"Blood"},{"key":"2019081609500511600_key151-B37","article-title":"A phase 2 study of pomalidomide (CC-4047) to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and effectiveness in subjects with systemic sclerosis with interstitial lung disease","volume":"68(Suppl 10)","author":"Hsu","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2019081609500511600_key151-B38","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1365-2796.2009.02207.x","article-title":"CD20-depleting therapy in autoimmune diseases: from basic research to the clinic","volume":"267","author":"Perosa","year":"2010","journal-title":"J Intern Med"},{"key":"2019081609500511600_key151-B39","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/rheumatology\/kep093","article-title":"Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study","volume":"49","author":"Daoussis","year":"2010","journal-title":"Rheumatology"},{"key":"2019081609500511600_key151-B40","article-title":"Myeloablative autologous transplantation of CD34+-selected hematopoietic stem cells (HSCT) vs monthly intravenous cyclophosphamide (CYC) for severe scleroderma with internal organ involvement: outcomes of a randomized North American clinical trial","volume":"68(Suppl S10)","author":"Sullivan","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2019081609500511600_key151-B41","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1001\/jama.2014.6368","article-title":"Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial","volume":"311","author":"van Laar","year":"2014","journal-title":"JAMA"},{"key":"2019081609500511600_key151-B42","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/bmt.2016.211","article-title":"Autologous hematopoietic stem cell transplantation has better outcomes than conventional therapies in patients with rapidly progressive systemic sclerosis","volume":"52","author":"Del Papa","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"2019081609500511600_key151-B43","doi-asserted-by":"crossref","first-page":"160080","DOI":"10.1183\/16000617.0080-2016","article-title":"Oxygen therapy for interstitial lung disease: a systematic review","volume":"26","author":"Bell","year":"2017","journal-title":"Eur Respir Rev"},{"key":"2019081609500511600_key151-B44","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1378\/chest.08-1458","article-title":"Pulmonary rehabilitation in interstitial lung disease: benefits and predictors of response","volume":"135","author":"Ferreira","year":"2009","journal-title":"Chest"},{"key":"2019081609500511600_key151-B45","first-page":"CD006322","article-title":"Pulmonary rehabilitation for interstitial lung disease","volume":"10","author":"Dowman","year":"2014","journal-title":"The Cochrane Database Syst Rev"},{"key":"2019081609500511600_key151-B46","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1503\/cmaj.110024","article-title":"The use of opioids for dyspnea in advanced disease","volume":"183","author":"Gallagher","year":"2011","journal-title":"Can Med Assoc J"},{"key":"2019081609500511600_key151-B47","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1513\/AnnalsATS.201512-806OC","article-title":"Lung transplant outcomes in systemic sclerosis with significant esophageal dysfunction. A comprehensive single-center experience","volume":"13","author":"Miele","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"2019081609500511600_key151-B48","doi-asserted-by":"crossref","first-page":"247","DOI":"10.5301\/jsrd.5000214","article-title":"Gastrointestinal manifestations of systemic sclerosis","volume":"1","author":"Shreiner","year":"2016","journal-title":"J Scleroderma Relat Disord"},{"key":"2019081609500511600_key151-B49","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/s13063-017-2016-2","article-title":"Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial","volume":"18","author":"Saunders","year":"2017","journal-title":"Trials"},{"key":"2019081609500511600_key151-B50","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.tips.2012.04.002","article-title":"Integrins as therapeutic targets","volume":"33","author":"Goodman","year":"2012","journal-title":"Trends Pharmacol Sci"},{"key":"2019081609500511600_key151-B51","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0959-437X(00)00155-6","article-title":"Coordinate signaling by integrins and receptor tyrosine kinases in the regulation of G1 phase cell-cycle progression","volume":"11","author":"Assoian","year":"2001","journal-title":"Curr Opin Genet Dev"},{"key":"2019081609500511600_key151-B52","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1006\/excr.2000.5040","article-title":"Multiple roles of integrins in cell motility","volume":"261","author":"Holly","year":"2000","journal-title":"Exp Cell Res"},{"key":"2019081609500511600_key151-B53","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nrc727","article-title":"Role of integrins in cell invasion and migration","volume":"2","author":"Hood","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"2019081609500511600_key151-B54","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nrm1789","article-title":"ILK, PINCH and parvin: the tIPP of integrin signalling","volume":"7","author":"Legate","year":"2006","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2019081609500511600_key151-B55","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1080\/07357900701522638","article-title":"Alpha-v integrins as therapeutic targets in oncology","volume":"25","author":"Nemeth","year":"2007","journal-title":"Cancer Invest"},{"key":"2019081609500511600_key151-B56","doi-asserted-by":"crossref","first-page":"208219","DOI":"10.1155\/2011\/208219","article-title":"Blocking TGF\u03b2 via inhibition of the \u03b1v\u03b26 integrin: a possible therapy for systemic sclerosis interstitial lung disease","volume":"2011","author":"Katsumoto","year":"2011","journal-title":"Int J Rheumatol"},{"key":"2019081609500511600_key151-B57","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1164\/rccm.200706-805OC","article-title":"Partial inhibition of integrin \u03b1v\u03b26 prevents pulmonary fibrosis without exacerbating inflammation","volume":"177","author":"Horan","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"2019081609500511600_key151-B58","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/S0002-9440(10)63215-4","article-title":"Increased expression levels of integrin \u03b1v\u03b25 on scleroderma fibroblasts","volume":"164","author":"Asano","year":"2004","journal-title":"Am J Pathol"},{"key":"2019081609500511600_key151-B59","doi-asserted-by":"crossref","first-page":"7708","DOI":"10.4049\/jimmunol.175.11.7708","article-title":"Increased expression of integrin \u03b1v\u03b23 contributes to the establishment of autocrine TGF-\u03b2 signaling in scleroderma fibroblasts","volume":"175","author":"Asano","year":"2005","journal-title":"J Immunol"},{"key":"2019081609500511600_key151-B60","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s10637-013-0038-5","article-title":"Safety, tolerability, and pharmacokinetics of the novel \u03b1v-integrin antibody EMD 525797 (DI17E6) in healthy subjects after ascending single intravenous doses","volume":"32","author":"Uhl","year":"2014","journal-title":"Invest New Drugs"},{"key":"2019081609500511600_key151-B61","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.eururo.2013.05.051","article-title":"A multicenter phase 1 study of EMD 525797 (DI17E6), a novel humanized monoclonal antibody targeting \u03b1v integrins, in progressive castration-resistant prostate cancer with bone metastases after chemotherapy","volume":"65","author":"Wirth","year":"2014","journal-title":"Eur Urol"},{"key":"2019081609500511600_key151-B62","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1158\/1078-0432.CCR-15-2512","article-title":"Differential effect on bone lesions of targeting integrins: randomized phase II trial of abituzumab in patients with metastatic castration-resistant prostate cancer","volume":"22","author":"Hussain","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2019081609500511600_key151-B63","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1093\/annonc\/mdu474","article-title":"Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I\/II POSEIDON trial","volume":"26","author":"Elez","year":"2015","journal-title":"Ann Oncol"},{"key":"2019081609500511600_key151-B64","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.2217\/imt.15.66","article-title":"Modulatory effects of bortezomib on host immune cell functions","volume":"7","author":"Pellom","year":"2015","journal-title":"Immunotherapy"},{"key":"2019081609500511600_key151-B65","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1136\/thoraxjnl-2011-200717","article-title":"Proteasomal inhibition after injury prevents fibrosis by modulating TGF-\u03b21 signalling","volume":"67","author":"Mutlu","year":"2012","journal-title":"Thorax"},{"key":"2019081609500511600_key151-B66","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/nrrheum.2011.149","article-title":"Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities","volume":"8","author":"Bhattacharyya","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"2019081609500511600_key151-B67","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1358\/dof.2005.030.09.938760","article-title":"Dabigatran\/dabigatran etexilate","volume":"30","author":"Sorbera","year":"2005","journal-title":"Drugs Future"},{"key":"2019081609500511600_key151-B68","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1002\/art.24935","article-title":"Dabigatran, a direct thrombin inhibitor, demonstrates antifibrotic effects on lung fibroblasts","volume":"60","author":"Bogatkevich","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2019081609500511600_key151-B69","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1002\/art.30255","article-title":"Antiinflammatory and antifibrotic effects of the oral direct thrombin inhibitor dabigatran etexilate in a murine model of interstitial lung disease","volume":"63","author":"Bogatkevich","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2019081609500511600_key151-B70","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1183\/09031936.00174914","article-title":"Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis","volume":"45","author":"Wollin","year":"2015","journal-title":"Eur Respir J"},{"key":"2019081609500511600_key151-B71","first-page":"75","article-title":"Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS)","volume":"35(Suppl 106)","author":"Distler","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"2019081609500511600_key151-B72","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.3899\/jrheum.151322","article-title":"An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS trial","volume":"43","author":"Khanna","year":"2016","journal-title":"J Rheumatol"},{"key":"2019081609500511600_key151-B73","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.2147\/DDDT.S99696","article-title":"Spotlight on tocilizumab and its potential in the treatment of systemic sclerosis","volume":"10","author":"Sakkas","year":"2016","journal-title":"Drug Des Devel Ther"},{"key":"2019081609500511600_key151-B74","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.pupt.2017.05.007","article-title":"IL-13 and idiopathic pulmonary fibrosis: possible links and new therapeutic strategies","volume":"45","author":"Passalacqua","year":"2017","journal-title":"Pulm Pharmacol Ther"},{"key":"2019081609500511600_key151-B75","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/nrd4382","article-title":"InterMune and Boehringer blaze trails for idiopathic pulmonary fibrosis drugs","volume":"13","author":"Kingwell","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"2019081609500511600_key151-B76","doi-asserted-by":"crossref","first-page":"v27","DOI":"10.1093\/rheumatology\/kex203","article-title":"Interstitial lung disease points to consider for clinical trials in systemic sclerosis","volume":"56(Suppl_5)","author":"Khanna","year":"2017","journal-title":"Rheumatology"},{"key":"2019081609500511600_key151-B77","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1002\/art.39797","article-title":"An autotaxin\/lysophosphatidic acid\/interleukin-6 amplification loop drives scleroderma fibrosis","volume":"68","author":"Castelino","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2019081609500511600_key151-B78","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1182\/blood-2017-01-758854","article-title":"Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-\u03b2 production","volume":"129","author":"Du","year":"2017","journal-title":"Blood"},{"key":"2019081609500511600_key151-B79","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1053\/j.seminhematol.2010.01.011","article-title":"Rituximab: mechanism of action","volume":"47","author":"Weiner","year":"2010","journal-title":"Semin Hematol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/58\/4\/567\/28719627\/key151.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T16:59:33Z","timestamp":1720285173000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/58\/4\/567\/5035083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,8]]},"references-count":79,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,6,8]]},"published-print":{"date-parts":[[2019,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/key151","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,4]]},"published":{"date-parts":[[2018,6,8]]}}}